These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33505147)

  • 1. Experimental models of metabolic and alcoholic fatty liver disease.
    Buyco DG; Martin J; Jeon S; Hooks R; Lin C; Carr R
    World J Gastroenterol; 2021 Jan; 27(1):1-18. PubMed ID: 33505147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis.
    Hellerbrand C
    Dig Dis; 2010; 28(6):783-91. PubMed ID: 21525763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.
    Marventano S; Salomone F; Godos J; Pluchinotta F; Del Rio D; Mistretta A; Grosso G
    Clin Nutr; 2016 Dec; 35(6):1269-1281. PubMed ID: 27060021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease versus Alcohol-related Liver Disease: Is it Really so Different?
    Craciun A; Lackner C; Cortez-Pinto H
    Curr Pharm Des; 2020; 26(10):1093-1109. PubMed ID: 31969088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD).
    Alwahsh SM; Gebhardt R
    Arch Toxicol; 2017 Apr; 91(4):1545-1563. PubMed ID: 27995280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
    Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).
    Senussi NH; McCarthy DM
    Ann Hepatol; 2021; 24():100526. PubMed ID: 34509272
    [No Abstract]   [Full Text] [Related]  

  • 11. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress.
    Sakaguchi S; Takahashi S; Sasaki T; Kumagai T; Nagata K
    Drug Metab Pharmacokinet; 2011; 26(1):30-46. PubMed ID: 21150132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual alcohol and metabolic-related liver disease: Results from a population of liver transplant patients.
    Erard D; Villeret F; Chouik Y; Guillaud O; Scoazec JY; Caussy C; Disse E; Boillot O; Hervieu V; Dumortier J
    Liver Int; 2024 Feb; 44(2):422-432. PubMed ID: 38010979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies.
    Åberg F; Färkkilä M; Männistö V
    Alcohol Clin Exp Res; 2020 Feb; 44(2):384-403. PubMed ID: 31854001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
    Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
    Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.
    Soto-Angona Ó; Anmella G; Valdés-Florido MJ; De Uribe-Viloria N; Carvalho AF; Penninx BWJH; Berk M
    BMC Med; 2020 Oct; 18(1):261. PubMed ID: 32998725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Mahli A; Hellerbrand C
    Dig Dis; 2016; 34 Suppl 1():32-9. PubMed ID: 27548267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease.
    Leung TM; Nieto N
    J Hepatol; 2013 Feb; 58(2):395-8. PubMed ID: 22940046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?
    Tarantino G; Finelli C
    World J Gastroenterol; 2013 Jun; 19(22):3375-84. PubMed ID: 23801829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey.
    Kotronen A; Yki-Järvinen H; Männistö S; Saarikoski L; Korpi-Hyövälti E; Oksa H; Saltevo J; Saaristo T; Sundvall J; Tuomilehto J; Peltonen M
    BMC Public Health; 2010 May; 10():237. PubMed ID: 20459722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.
    Ratziu V; Ghabril M; Romero-Gomez M; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):28-38. PubMed ID: 30300289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.